NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
Clinical Trials
9 trialsNCT06528301 2026-01-12
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
Phase 1 Recruiting
NCT03363763 2025-12-01
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Aucta Pharmaceuticals, Inc
Phase 2 Terminated
NCT07241936 2025-11-28
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Recruiting
NCT06743503 2025-09-18
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Nanjing IASO Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT07165886 2025-09-10
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3 Recruiting
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06929325 2025-04-16
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting